CABA earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -1.40. Updated 2026-07-23.
Cabaletta Bio (CABA) Research Hub
Cabaletta Bio (CABA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.73 USD (-6.19%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.40, market cap 0.44B. This hub links to the full technical, earnings and options research available for CABA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.73 USD (-6.19%) |
| 52-week range | 2.59 USD – 3.75 USD |
| Trend regime | Range |
| 14-day RSI | 48.4 (Neutral) |
| Trailing P/E | -1.40 |
| Market cap | 0.44B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for CABA
Covered Call on CABA: how it works, illustrative setup around the real 2.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CABA: how it works, illustrative setup around the real 2.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CABA: how it works, illustrative setup around the real 2.73 USD price, max profit/loss, breakeven and when to use it. Educational.
CABA technical analysis: range, last 2.73 USD, RSI 48.4, 52w range 2.59 USD–3.75 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CABA in?
Cabaletta Bio (CABA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CABA in an uptrend or downtrend?
As of 2026-09-11, CABA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CABA's trailing P/E ratio?
CABA's trailing P/E is -1.40, with a market cap of 0.44B. See the earnings research page for full valuation detail.
When does CABA next report earnings?
CABA is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.37 USD.